Extracorporeal high intensity focused ultrasound for renal tumours: a 3‐year follow‐up
- 14 September 2010
- journal article
- Published by Wiley in BJU International
- Vol. 106 (7) , 1004-1009
Abstract
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE: To determine whether primary extracorporeal high‐intensity focused ultrasound (HIFU) is safe, feasible and effective for managing small renal tumours. PATIENTS AND METHODS: Although surgery currently remains the standard treatment for localized renal cell carcinoma (RCC), the increasing incidence of small renal cancers has led to a shift towards nephron‐sparing surgery, with associated morbidity in 20–25% of cases, and minimally invasive ablative therapies present an alternative management. HIFU results in ‘trackless’ homogenous tissue ablation and when administered via an extracorporeal device, is entirely noninvasive. The study comprised 17 patients (mean tumour size 2.5 cm) with radiologically suspicious renal tumours who underwent extracorporeal HIFU using the Model‐JC System (Chongqing HAIFU TM , China), under general anaesthesia with one overnight hospital stay. Real‐time diagnostic ultrasonography was used for targeting and monitoring. Patients were followed with a clinical review and gadolinium‐enhanced magnetic resonance imaging at 12 days and every 6 months for a mean of 36 months. The outcomes measures were patient morbidity and oncological efficacy of HIFU treatment. RESULTS: Of the 17 patients, 15 were treated according to protocol; two procedures were abandoned due to intervening bowel. There were no major complications related to HIFU. Radiological evidence of ablation was apparent at 12 days in seven of the 15 patients. Before the 6‐month follow‐up one patient had surgery due to persisting central enhancement. Fourteen patients were evaluated at the 6‐month follow‐up; eight tumours had involuted (mean 12% decrease in tumour area). Four patients had irregular enhancement on imaging and had alternative therapies. Ten patients remain on follow‐up at a mean (range) of 36 (14–55) months after HIFU (mean 30% decrease in tumour area). There was central loss of enhancement in all. CONCLUSIONS: Renal HIFU achieves stable lesions in two‐thirds of patients, with minimal morbidity, and might be appropriate in selected cases. Further trials with accurate histological follow‐up are essential to fully evaluate this novel technique.Keywords
This publication has 31 references indexed in Scilit:
- Cryoablation or radiofrequency ablation of the small renal massCancer, 2008
- A Novel Approach to Energy Ablative Therapy of Small Renal Tumours: Laparoscopic High-Intensity Focused UltrasoundEuropean Urology, 2008
- Is Surveillance an Option for the Treatment of Small Renal Masses?European Urology, 2007
- Investigation of HIFU-induced anti-tumor immunity in a murine tumor modelJournal of Translational Medicine, 2007
- Extracorporeally induced ablation of renal tissue by high‐intensity focused ultrasoundBJU International, 2006
- Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCsBiochemical and Biophysical Research Communications, 2005
- In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor ImmunityCancer Research, 2004
- Preliminary Experience Using High Intensity Focused Ultrasound for the Treatment of Patients With Advanced Stage Renal MalignancyJournal of Urology, 2003
- Incidental renal cell carcinoma—age and stage characterization and clinical implications: study of 1092 patients (1982–1997)Urology, 2000
- High intensity focused ultrasound-a surgical technique for the treatment of discrete liver tumoursPhysics in Medicine & Biology, 1989